Navigating Critical Updates in Advanced Breast Cancer Management From ASCO 2026

Dato-DXd led to benefits in terms of TFST, PFS2, and TSST vs chemotherapy in frontline TNBC.

A switch to camizestrant upon emergence of an ESR1 mutation improved PFS2 in ER-positive, HER2-negative advanced breast cancer.

Giredestrant plus palbociclib improved PFS numerically just shy of 5 months in the persevERA trial, but was deemed negative due to lack of statistical significance.